These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26648321)

  • 1. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.
    Hayashi N; Ando Y; Gyawali B; Shimokata T; Maeda O; Fukaya M; Goto H; Nagino M; Kodera Y
    Oncol Rep; 2016 Mar; 35(3):1727-31. PubMed ID: 26648321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
    Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
    Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of muscle and adipose tissue parameters with long-term outcomes in middle and low rectal cancer: a retrospective cohort study.
    Liu J; Yu X; Huang X; Lai Q; Chen J
    Cancer Imaging; 2023 Jan; 23(1):5. PubMed ID: 36635737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
    Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
    Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch AR; Chua NS; Fontaine A; Sangha R; Turner AR; Baracos VE; Sawyer MB
    PLoS One; 2015; 10(6):e0127589. PubMed ID: 26030144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of sarcopenia with severe chemotherapy toxicities and survival in patients with advanced gastric cancer.
    Chan WL; Yun HB; Cheung EE; Liu M; Hou LY; Lam KO; Wong IY; Chiu WK; Law S; Kwong D
    Oncologist; 2024 Oct; 29(10):e1272-e1279. PubMed ID: 38885304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer.
    Ganju RG; TenNapel M; Spoozak L; Chen AM; Hoover A
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):104-112. PubMed ID: 31397078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between low skeletal muscle mass and low skeletal muscle radiodensity with functional impairment, systemic inflammation, and reduced survival in patients with incurable cancer.
    Calixto-Lima L; Wiegert EVM; Oliveira LC; Chaves GV; Bezerra FF; Avesani CM
    JPEN J Parenter Enteral Nutr; 2023 Feb; 47(2):265-275. PubMed ID: 36325962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
    Lee JS; Kim YS; Kim EY; Jin W
    PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative skeletal muscle index vs the controlling nutritional status score: Which is a better objective predictor of long-term survival for gastric cancer patients after radical gastrectomy?
    Zheng ZF; Lu J; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P
    Cancer Med; 2018 Aug; 7(8):3537-3547. PubMed ID: 29953752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.
    Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
    Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
    Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
    Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.